Working… Menu

Minimally Invasive Benign Hysterectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01865929
Recruitment Status : Unknown
Verified May 2013 by Celine Lönnerfors, Region Skane.
Recruitment status was:  Recruiting
First Posted : May 31, 2013
Last Update Posted : May 31, 2013
Information provided by (Responsible Party):
Celine Lönnerfors, Region Skane

Brief Summary:
A randomised controlled trial comparing hysterectomy by minimally invasive surgical methods; robotic hysterectomy versus vaginal hysterectomy or traditional laparoscopic hysterectomy; outcome and cost analyses.

Condition or disease Intervention/treatment Phase
Menorrhagia Metrorrhagia Uterine Fibroids Cervical Dysplasia Device: Robotic hysterectomy Procedure: Vaginal or laparoscopic hysterectomy Not Applicable

Detailed Description:

Laparoscopic surgery is advantageous compared to open surgery in terms of patient morbidity, shorter hospitalization and a more rapid return to daily activities. Robot-assisted laparoscopic surgery have facilitated a higher proportion of minimally invasive surgery first and foremost within gynecologic oncology.It is not clear whether or not this is true for less advanced surgery where a vaginal approach or a traditional laparoscopic approach is possible.

Robot-assisted surgery is associated with additional cost due to investment and more expensive surgical equipment. The study is performed to investigate whether or not performing hysterectomy for benign conditions with robotic surgery will be advantageous in terms of shorter operating time, less complications, less conversions to open surgery, and shorter hospital stay in comparison to other minimally invasive procedures such as vaginal hysterectomy and traditional laparoscopic hysterectomy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Benign Hysterectomy; a Randomized Controlled Trial Comparing Robotic Hysterectomy With Vaginal Hysterectomy and Traditional Laparoscopic Hysterectomy
Study Start Date : January 2010
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hysterectomy

Arm Intervention/treatment
Active Comparator: Robotic hysterectomy
Minimally invasive hysterectomy by robotic surgery
Procedure: Vaginal or laparoscopic hysterectomy
Benign hysterectomy performed by traditional minimal invasive procedures.

Active Comparator: Vaginal or laparoscopic hysterectomy
Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
Device: Robotic hysterectomy
Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
Other Name: da Vinci Surgical system, Intuitive Surgical Inc, CA, USA

Primary Outcome Measures :
  1. Cost of surgery [ Time Frame: 4 months ]
    The cost of surgery includes the actual surgery (anaesthesia, OR-nurse, circulating nurse, doctors and use of the OR) as well as the length of the inpatient stay. The cost for conversions to open surgery, reoperations, readmissions, and any additional cost associated with additional procedures or medical interventions such as radiological examinations and blood transfusions. Based on the estimated cost of surgical material, use of the operating room and cost of anaesthesia each benign hysterectomy performed with robotic surgery would need to be 50 minutes shorter than other minimal invasive procedures to compensate for the additional cost.

Secondary Outcome Measures :
  1. Patient outcome [ Time Frame: 4 months ]
    The number of patients in whom an intraoperative or postoperative complication occurs as well as the seriousness of the complication which occurs and what this entails for the patient in question. This includes conversions to open surgery as well as the need for reoperation and readmission.

Other Outcome Measures:
  1. Social cost [ Time Frame: 4 months ]
    The length of postoperative sick leave and reasons for extending sick leave and cost thereof.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • indication for hysterectomy for benign disease or prophylactic surgery due to hereditary cancer
  • size of uterus and vagina allows for retrieval by the vaginal route
  • maximum uterine size equivalent to 16 weeks of pregnancy
  • informed consent

Exclusion Criteria:

  • malignant disease
  • known extensive intra-abdominal adhesions
  • anaesthesiological contraindications to laparoscopic surgery
  • women with pacemaker or other implants where electrosurgery is to be avoided
  • immunoincompetent women
  • simultaneous need for prolapse surgery
  • women with known defects of the hemostasis
  • allergies towards metronidazole and doxycycline
  • inability to understand patient information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01865929

Layout table for location contacts
Contact: Jan Persson, MD, PhD +4646171000
Contact: Celine Lönnerfors, MD +4646171000

Layout table for location information
Department of Obstetrics and Gynecology, Skane University Hospital Recruiting
Lund, Sweden, 221 85
Contact: Jan Persson, MD, PhD   
Principal Investigator: Jan Persson, MD, PhD         
Sub-Investigator: Celine Lönnerfors, MD         
Sponsors and Collaborators
Region Skane
Layout table for investigator information
Study Director: Jan Persson, MD, PhD Department of Obstetrics and Gynecology, Skane University Hospital, Lund

Layout table for additonal information
Responsible Party: Celine Lönnerfors, Medical Doctor, Region Skane Identifier: NCT01865929     History of Changes
Other Study ID Numbers: LundKK
First Posted: May 31, 2013    Key Record Dates
Last Update Posted: May 31, 2013
Last Verified: May 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Dysplasia
Cervical Intraepithelial Neoplasia
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Pathologic Processes
Menstruation Disturbances
Precancerous Conditions
Uterine Cervical Diseases
Carcinoma in Situ
Neoplasms, Glandular and Epithelial